Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)

Phase 2

Terminated

Conditions: Autoimmune Hepatitis
Autoimmune Chronic Hepatitis

Interventions: Other: Placebo
Drug: RO7049665

First Posted Date: 2021-03-10

Last Posted Date: 2023-09-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2

Registration Number: NCT04790916

Locations: 🇦🇺
The Alfred Hospital - Professor Stuart Roberts' Clinic - The Alfred Centre Location, Melbourne, Victoria, Australia
🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇩🇪
Martin Zeitz Centrum für Seltene Erkrankungen ZSE Hamburg, Hamburg, Germany

and more 11 locations

A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Phase 2

Completed

Conditions: Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Interventions: Drug: Lomvastomig
Drug: Tobemstomig
Drug: Nivolumab

First Posted Date: 2021-03-08

Last Posted Date: 2025-03-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 206

Registration Number: NCT04785820

Locations: 🇦🇷
Inst. Alexander Fleming, Buenos Aires, Argentina
🇦🇷
Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina
🇧🇷
Hospital das Clinicas - UFRGS, Porto Alegre, Rio Grande Do Sul, Brazil

and more 50 locations

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

Phase 2

Active, not recruiting

Conditions: Parkinsons Disease

Interventions: Drug: Prasinezumab
Drug: Placebo

First Posted Date: 2021-03-02

Last Posted Date: 2025-04-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 586

Registration Number: NCT04777331

Locations: 🇺🇸
Dent Neurological Institute, Amherst, New York, United States
🇮🇹
A.O.U. Policlinico "G.Rodolico - San Marco", Catania, Sicilia, Italy
🇮🇹
A.O. Universitaria Pisana, Pisa, Toscana, Italy

and more 107 locations

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

Phase 3

Completed

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: Faricimab
Other: Sham Procedure

First Posted Date: 2021-03-02

Last Posted Date: 2024-12-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1036

Registration Number: NCT04777201

Locations: 🇺🇸
Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
🇺🇸
Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States
🇺🇸
Associated Retina Consultants, Phoenix, Arizona, United States

and more 251 locations

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Phase 1

Recruiting

Conditions: ALK Fusion-positive Solid or CNS Tumors

Interventions: Drug: Alectinib

First Posted Date: 2021-03-01

Last Posted Date: 2025-06-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 42

Registration Number: NCT04774718

Locations: 🇺🇸
Lucile Packard Children's Hospital, Palo Alto, California, United States
🇺🇸
Children's Minnesota, Minneapolis, Minnesota, United States
🇧🇷
Hospital de Cancer de Barretos, Barretos, São Paulo, Brazil

and more 30 locations

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

Phase 3

Active, not recruiting

Conditions: Unresectable Hepatocellular Carcinoma

Interventions: Drug: Atezolizumab
Drug: Lenvatinib
Drug: Sorafenib

First Posted Date: 2021-02-25

Last Posted Date: 2025-05-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 554

Registration Number: NCT04770896

Locations: 🇨🇳
Fujian Provincial Hospital, Fuzhou City, China
🇦🇹
Medizinische Universität Innsbruck, Innsbruck, Austria
🇦🇹
Uniklinikum Salzburg, LKH, Salzburg, Austria

and more 119 locations

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

Active, not recruiting

Conditions: NSCLC

Interventions: Drug: Alectinib

First Posted Date: 2021-02-21

Last Posted Date: 2025-04-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 800

Registration Number: NCT04764188

Locations: 🇦🇷
Clinica Adventista Belgrano, Ciudad Autonoma Buenos Aires, Argentina
🇦🇺
Lifehouse, Camperdown, New South Wales, Australia
🇦🇺
Liverpool Hospital, Liverpool, New South Wales, Australia

and more 113 locations

A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

Phase 3

Withdrawn

Conditions: Medullary Thyroid Cancer

Interventions: Drug: Pralsetinib
Drug: Cabozantinib
Drug: Vandetanib

First Posted Date: 2021-02-18

Last Posted Date: 2024-01-05

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT04760288

Locations: 🇪🇸
Hospital Universitario Virgen del Rocio, Sevilla, Spain

A Study To Monitor Lung Cancer Patients Activity And Assess Performance Status Through A Wearable Device.

Completed

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Device: Actigraphy device (wearable) and mobile application

First Posted Date: 2021-02-11

Last Posted Date: 2023-06-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 71

Registration Number: NCT04751162

Locations: 🇪🇸
Hospital La Paz, Madrid, Spain
🇪🇸
Hospital Universitari de Girona Dr Josep Trueta; Departamento de Oncologia Medica, Girona, Spain
🇪🇸
Fundacion Hospital de Alcorcon, Alcorcon, Madrid, Spain

and more 7 locations

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

Phase 3

Completed

Conditions: Macular Edema
Branch Retinal Vein Occlusion

Interventions: Drug: Faricimab
Drug: Aflibercept
Procedure: Sham Procedure

First Posted Date: 2021-02-05

Last Posted Date: 2024-08-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 553

Registration Number: NCT04740905

Locations: 🇵🇱
Gabinet Okulistyczny Prof Edward Wylegala, Katowice, Poland
🇺🇸
Cumberland Valley Retina PC, Hagerstown, Maryland, United States
🇦🇺
The Lions Eye Institute, Nedlands, Western Australia, Australia

and more 147 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy